Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy

Eric Van Cutsem, Florence Joulain, Paulo M. Hoff, Edith Mitchell, Paul Ruff, Radek Lakomý, Jana Prausová, Vladimir M. Moiseyenko, Guy van Hazel, David Cunningham, Dirk Arnold, Hans Joachim Schmoll, Albert J. ten Tije, Joseph McKendrick, Hendrik Kröning, Yves Humblet, Cristina Grávalos, Solenn Le-Guennec, Michael Andria, Emmanuelle DochyRaghu L. Vishwanath, Teresa Macarulla, Josep Tabernero

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Fingerprint Dive into the research topics of 'Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences